UK markets open in 6 hours 10 minutes

Photocure ASA (0IMT.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
49.75-0.45 (-0.90%)
At close: 04:45PM GMT
Full screen
Previous close50.20
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Avg. volume7,089
Market cap9.729M
Beta (5Y monthly)0.79
PE ratio (TTM)N/A
EPS (TTM)-2.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

    Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China. Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.

  • PR Newswire

    Photocure to present at four investor conferences in November/December 2023

    Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:

  • PR Newswire

    Photocure ASA: Results for the third quarter of 2023

    Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company. Photocure refines its guidance ranges for 2023: The Company continues to expect 65-75 new Saphira™ blue light tower installations assuming delivery of an anticipated large purchase order in Q4; consolidated product revenue growth in the range of 17-20% including the impact of FX and the